1 active not recruiting, 1 completed, 1 recruiting, 1 terminated. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow CYH33: new trials by email Literature Review of CYH33 trials Research Report on CYH33
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM) CYH33, Placebo - PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM) | Phase 1 / Phase 2 | Recruiting | Haihe Biopharma Co., Ltd. | 141 | 2023-08-22 | 2026-06-29 |
| A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma CYH33 - Ovarian Cancer, Recurrent Cancer | Phase 2 | Active not recruiting | Haihe Biopharma Co., Ltd. | 93 | 2021-10-11 | 2026-01-30 |
| Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer CYH33, Fulvestrant, Letrozole - Advanced Breast Cancer | Phase 1 | Unknown | Haihe Biopharma Co., Ltd. | 228 | 2021-04-01 | 2021-04-23 |
| Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. CYH33 - Ovarian Cancer, Breast Cancer | Phase 1 | Terminated | Haihe Biopharma Co., Ltd. | 24 | 2020-09-28 | 2024-03-21 |
| Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33 CYH33 for tablet - Advanced Solid Tumors | Phase 1 | Completed | Haihe Biopharma Co., Ltd. | 206 | 2018-07-05 | 2025-04-22 |
Ovarian Neoplasms (2) · Breast Neoplasms (1) · Endometrial Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Prostatic Neoplasms (1) · Recurrence (1)
China (4) · Japan (2) · Australia (1) · United States (1)
Fugen Li, PhD (1) · Ruihua Xu, M.D (1)